3 biotech babies that could boom

Analytica (ALT, market cap. $31 million)

Analytica’s lead product is the PeriCoach system, an mHealth treatment system for women who suffer Stress Urinary Incontinence. This condition affects one in three women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.
PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. The system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.
PeriCoach has been approved in Australia and Europe, with product launches expected in 2015, and in the US also next year. The system is about to enter clinical trials in Australia, but these are not required for any regulatory approvals: they are being done to provide formal evidence of the system’s efficacy.
Analytica is also commercialising the AutoStart Infusion System, a system for the regular monitoring and controlled refilling of burettes in intravenous fluid infusion. The company says it is targeting a $3 billion global market with AutoStart, which has been approved by the FDA, and Analytica has struck distribution agreements.
For the year to 30 June 2014, Analytica received $565,174 in grant, royalty and investment revenue, up 9%, but all of its expenses – mostly wages, marketing and research and development – pushed it to a net loss of $3.2 million. That can be expected to improve once it starts selling its products

http://learn.nabtrade.com.au/discover/articles/3-biotech-babies-that-could-boom